<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05003362</url>
  </required_header>
  <id_info>
    <org_study_id>2018P001239</org_study_id>
    <nct_id>NCT05003362</nct_id>
  </id_info>
  <brief_title>ACT for High Frequency Migraine; A Virtual Mindfulness Intervention</brief_title>
  <official_title>Acceptance and Commitment Therapy for High Frequency Episodic Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mindfulness Training specifically for pain to be offered to migraine patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with high frequency migraine will be randomized to UC or intervention. Those in&#xD;
      intervention will attend a multi session training on Acceptance and Commitment Therapy. All&#xD;
      participants will track responses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>After screening, patients will be randomized and one group will receive the intervention. The investigators will do sequential interventions of the ACT</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>randomized control</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of a randomized controlled trial of ACT</measure>
    <time_frame>one year</time_frame>
    <description>Demonstrate that 48 patients can be successfully enrolled and randomized</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preliminary data on the effectiveness of ACT on migraine frequency and migraine disability</measure>
    <time_frame>one year</time_frame>
    <description>Patient-completed migraine logs will be used to record the number of migraine days/month. Migraine disability will be measured using the validated Migraine Disability Assessment (MIDAS) questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in migraine severity, duration, and medication use.</measure>
    <time_frame>one year</time_frame>
    <description>Severity of each migraine (1-10), duration (hours), and medicines taken assessed by patient-completed migraine logs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in headache-related disability</measure>
    <time_frame>one year</time_frame>
    <description>Headache Related Disability measured using the validated HIT-6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life.</measure>
    <time_frame>one year</time_frame>
    <description>Quality of life assessed using the Migraine Specific Quality of Life Questionnaire (MSQ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in depression and anxiety.</measure>
    <time_frame>one year</time_frame>
    <description>Depression and anxiety assessed through the Hospital Anxiety and Depression Scale (HADS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain acceptance and pain expectancy.</measure>
    <time_frame>one year</time_frame>
    <description>Pain acceptance assessed through the Chronic Pain Acceptance Questionnaire and pain expectancy during the migraine attacks assessed using the allodynia questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain catastrophizing.</measure>
    <time_frame>one year</time_frame>
    <description>Pain Catastrophizing Scale (PCS) used to assess distress and rumination experienced due to migraine anticipation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in distress tolerance.</measure>
    <time_frame>one year</time_frame>
    <description>Distress tolerance will be assessed through the Distress Tolerance Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in physical activity.</measure>
    <time_frame>one year</time_frame>
    <description>Physical activity measured using the Godin Leisure Time Exercise questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in perceived stress.</measure>
    <time_frame>one year</time_frame>
    <description>Perceived stress measured through the Perceived Stress Scale (PSS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mindfulness.</measure>
    <time_frame>one year</time_frame>
    <description>Mindful Attention and Awareness Scale (MAAS) used to measure receptive awareness and attention to the present.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cortisol levels.</measure>
    <time_frame>one year</time_frame>
    <description>Salivary Cortisol will be collected to measure the cortisol awakening response.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects randomized to the usual care control group will continue using their usual medical care as prescribed by their physician.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>An 8-week mindfulness-based group therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>ACT</intervention_name>
    <description>mindfulness intervention for patients with pain/migraine</description>
    <arm_group_label>ACT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women ages 18-65&#xD;
&#xD;
          -  Diagnosis of episodic migraine (according to International Classification for Headache&#xD;
             Diagnosis criteria)&#xD;
&#xD;
          -  4-14 migraine days per month over the past 3 months&#xD;
&#xD;
          -  No change in medication in the past 3 months&#xD;
&#xD;
          -  Greater than 1 year of migraines&#xD;
&#xD;
          -  Agreeable to participate, commit to all study procedures and to be randomized to&#xD;
             either group&#xD;
&#xD;
          -  Fluent in English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any unstable medical or psychiatric conditions requiring immediate treatment or could&#xD;
             lead to difficulty complying with the protocol&#xD;
&#xD;
          -  Active suicidal ideation&#xD;
&#xD;
          -  Moderate to severe depression&#xD;
&#xD;
          -  Current alcohol or substance abuse&#xD;
&#xD;
          -  Recent Cognitive Behavioral Therapy, Mindfulness Based Cognitive Therapy, Dialectic&#xD;
             Behavioral Therapy or Acceptance and Commitment Therapy within past 3 years&#xD;
&#xD;
          -  Current use of narcotics&#xD;
&#xD;
          -  Psychiatric hospitalization within past year&#xD;
&#xD;
          -  Comorbid pain condition rated as more painful than migraine&#xD;
&#xD;
          -  Starts new migraine treatment during study&#xD;
&#xD;
          -  Inability to complete study visits&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>patients will identify as female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>carolyn bernstein, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>carolyn bernstein, md</last_name>
    <phone>617 732 9700</phone>
    <email>cabernstein@bwh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brigham and Womens Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>carolyn bernstein, md</last_name>
      <phone>617-732-9700</phone>
      <email>cabernstein@bwh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>carolyn bernstein, md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 20, 2021</study_first_submitted>
  <study_first_submitted_qc>August 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Carolyn A. Bernstein</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>migraine</keyword>
  <keyword>high frequency</keyword>
  <keyword>ACT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

